Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.45 |
| ▸ | F11 | P03951 | 9/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388404 | 1.00 | NR1H2 (0.49) | NR1H2ESR2KLKB1F11JAK2 | |
| SCHEMBL22993238 | 0.93 | HDAC1 (0.46) | NR1H2ESR2KLKB1F11HDAC1 | |
| SCHEMBL22981314 | 0.88 | F11 (0.47) | KLKB1F11 | |
| SCHEMBL29405107 | 0.85 | F11 (0.56) | KLKB1F11 | |
| SCHEMBL22982359 | 0.85 | F11 (0.56) | KLKB1F11 | |
| SCHEMBL29405895 | 0.84 | HDAC1 (0.45) | NR1H2ESR2KLKB1F11HDAC1 | |
| SCHEMBL24253253 | 0.83 | KLKB1 (0.47) | KLKB1F11 | |
| SCHEMBL22981213 | 0.82 | F11 (0.45) | KLKB1F11 | |
| SCHEMBL29405481 | 0.82 | F11 (0.52) | KLKB1F11 | |
| SCHEMBL22981499 | 0.77 | KLKB1 (0.48) | KLKB1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |